ARTICLE | Clinical News
Sepracor regulatory update
August 5, 1996 7:00 AM UTC
SEPR received three U.S. patents covering its Improved Chemical Entities (ICEs). Patent No. 5,532,278 covers the use of purified versions of S-oxybutynin, which is in Phase I/II trials to treat urinar...